Yüklüyor......

The bone marrow microenvironment as a sanctuary for minimal residual disease in CML

Bcr-abl kinase inhibitors have provided proof of principal that targeted therapy holds great promise for the treatment of cancer. However, despite the success of these agents in treating chronic myelogenous leukemia (CML), the majority of patients continue to present with minimal residual disease co...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Nair, Rajesh R., Tolentino, Joel, Hazlehurst, Lori A.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2010
Konular:
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3285111/
https://ncbi.nlm.nih.gov/pubmed/20382130
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bcp.2010.04.003
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!